GlassScriptPhysician profile
James Eric Whitworth
NPI 1790115798
$3,366.65
in general payments reported to CMS, 2019-2025
29 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,273 · 2023: $1,972 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $386.26 | 2022-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $380.64 | 2022-2023 | Mounjaro, Jardiance, Humulin |
| Bayer Healthcare Pharmaceuticals INC. | $263.17 | 2022-2023 | |
| Mannkind Corporation | $255.89 | 2022-2023 | Afrezza |
| Medtronic, INC. | $246.26 | 2022-2023 | Inpen Smart Insulin Delivery System |
| Amarin Pharma, INC. | $212.97 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $182.13 | 2022-2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $148.86 | 2022-2023 | Farxiga |
| Radius Health, INC. | $138.76 | 2022-2023 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.50 | 2022-2023 | Jardiance, Synjardy |
| Recordati_rare_diseases_inc. | $121.66 | 2025 | Isturisa |
| Merck Sharp & Dohme LLC | $110.68 | 2022-2023 | Steglatro |
| Insulet Corporation | $109.28 | 2023 | Omnipod |
| Amryt Pharma Holdings LTD | $98.64 | 2022-2023 | Mycapssa |
| Amgen INC. | $81.82 | 2023 | Evenity, Prolia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alvogen INC | $70.96 | 2022-2023 | Teriparatide |
| Amneal Pharmaceuticals LLC | $56.44 | 2022-2023 | Unithroid |
| Abbott Laboratories | $51.04 | 2022 | |
| Dexcom, INC. | $49.41 | 2022-2023 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $44.63 | 2022-2023 | Contrave |
| Abbvie INC. | $41.35 | 2023 | |
| Alexion Pharmaceuticals, INC. | $40.53 | 2023 | Strensiq |
| Lifescan, INC. | $32.36 | 2022 | |
| Ascendis Pharma Endocrinology INC | $26.95 | 2023 | |
| Sanofi-Aventis U.S. LLC | $23.74 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.74 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.88 | 2022 | |
| Pfizer INC. | $13.11 | 2023 | |
| Ibsa Pharma INC. | $12.99 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Whitworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.